Looking ahead, increased competition and the development of oral GLP-1 medications may help improve affordability and accessibility over time, she says
Cell Host & Microbe DOI:10.1016/j.chom.2026.05.003 Abstract Microbiota-driven gutbrain signaling underlies antidepressant effects of a GLP-1 analog Despite widespread clinical use of glucagon-like peptide-1 receptor (GLP-1R) agonists for metabolic disease, their neuropsychiatric effects remain poorly understood and controversial
Slower adjustments can help with fewer side effects but might delay reaching the full effectiveness of the medication
Common side effects include nausea, diarrhea, constipation, and fatigue, which often improve over time
Beyond glycaemic control, they slash cardiovascular risk by up to 26%, reduce the progression of kidney disease, and treat fatty liver and sleep apnoea, among others